The single-nucleotide polymorphism rs1990760 in the gene encoding the cytosolic viral sensor IFIH1 results in an amino-acid change (A946T; IFIH1 T946 ) that is associated with multiple autoimmune diseases. The effect of this polymorphism on both viral sensing and autoimmune pathogenesis remains poorly understood. Here we found that human peripheral blood mononuclear cells (PBMCs) and cell lines expressing the risk variant IFIH1 T946 exhibited heightened basal and ligand-triggered production of type I interferons. Consistent with those findings, mice with a knock-in mutation encoding IFIH1 T946 displayed enhanced basal expression of type I interferons, survived a lethal viral challenge and exhibited increased penetrance in autoimmune models, including a combinatorial effect with other risk variants. Furthermore, IFIH1 T946 mice manifested an embryonic survival defect consistent with enhanced responsiveness to RNA self ligands. Together our data support a model wherein the production of type I interferons driven by an autoimmune risk variant and triggered by ligand functions to protect against viral challenge, which probably accounts for its selection within human populations but provides this advantage at the cost of modestly promoting the risk of autoimmunity.
Autoimmune diseases arise from a complex interplay of genetic and environmental factors 1 . The anti-viral immune system includes several pathways in which the nexus of genetics, the environment and autoimmunity has become evident. Type I interferons and viral infection have each been associated with autoimmune diseases, including systemic lupus erythematosus (SLE) and type-1 diabetes (T1D) [2] [3] [4] , and genome-wide association studies have linked genes encoding products important for anti-viral immunity to those disorders. That association network emphasizes the delicate balance in selective pressure to mediate a more effective anti-viral response while limiting the risk for autoimmune sequelae. A striking example of that is IFIH1 ('interferon-induced helicase C-domain-containing protein 1'; also known as MDA5), a critical upstream component in the innate response of nearly all cell types to RNA viruses, including those in the Picornaviridae and Flaviviridae families [5] [6] [7] . IFIH1 contains two N-terminal caspase-activation-recruitment domains and a DExD/Hbox helicase domain followed by a C-terminal domain 8 . While the full repertoire of ligands recognized by IFIH1 remains to be defined, published work has shown that those viral families generate both long, double-stranded RNA (dsRNA) and branched, high-molecular-weight RNA that includes both dsRNA and single-stranded RNA, which stimulate signaling 9, 10 . Upon coordinated recognition of dsRNA by the C-terminal and helicase domains, IFIH1 undergoes conformational changes that lead to its oligomerization and assembly into filaments 7 and association of its caspase-activation-recruitment domain with the signaling effector MAVS ('mitochondrial anti-viral signaling protein'). That initiates signaling events that ultimately promote the transcription of genes encoding type I interferons and hundreds of interferon-stimulated genes (ISGs).
Gain-of-function missense mutations in IFIH1 that alter the helicase domain of IFIH1 have been identified in subjects with the rare, early-onset auto-inflammatory disorder Aicardi-Goutières syndrome, a type I interferonapathy 11 . The various mono-allelic mutations identified consistently alter the dsRNA-or ATP-binding sites within the helicase domain. Mutations that result in an activated IFIH1 helicase domain have also been identified in Singleton-Merten Syndrome, a rare disorder characterized by variable penetrance of dental and skeletal abnormalities and aortic and cardiac calcification 12 . In addition, an activating mutation in IFIH1 (resulting in the amino-acid substitution R779H), previously described in Aicardi-Goutières syndrome, has been identified in a single subject with early-onset SLE and immunoglobulin A (IgA) deficiency 13 . Similarly, N-ethyl-N-nitrosourea-mediated mutagenesis in mice has led to the identification of an interferon-dependent inflammatory disease that results from a gain-of-function Ifih1 mutation that alters the IFIH1 helicase domain 14 , although this specific mutation has not been associated with human disease.
In contrast to those penetrant, rare autosomal-dominant disorders, genome-wide association studies have identified both protective variants and risk variants of IFIH1 in various common human autoimmune diseases [15] [16] [17] [18] . One study has reported a significant allelic association with risk for T1D at rs1990760, a non-synonymous coding variant of IFIH1 (ref. 15 ). Subsequent studies have reported similarly significant associations of this single-nucleotide polymorphism (SNP) with other autoimmune diseases, including SLE, as well as suggestive findings or regional associations with many additional disorders, including psoriasis, rheumatoid arthritis, multiple sclerosis and vitiligo, indicative of a basic role for IFIH1 in the genesis of autoimmunity [17] [18] [19] [20] [21] . Subsequent re-sequencing of IFIH1 in patients with T1D and healthy control subjects has revealed that rare loss-of-function variants (including rs35667974, which leads to the amino-acid substitution I923V) are associated with protection from T1D 16 . In contrast to either rare loss-of-function variants or dominant mutations that promote auto-inflammatory disease, the rs1990760 risk allele is common, with an allele frequency of ~57% in European populations 22 , and it is predicted to result in an amino-acid change from alanine to threonine at codon 946 (A946T) within the C-terminal domain of IFIH1 (called 'IFIH1 T946 ' here) of unknown functional relevance.
While various studies have replicated and expanded the range of disorders associated with the IFIH1 T946 autoimmunity risk variant, there is little information about its effect on protein function and/or signaling activity. Most notably, its mechanistic effect(s) on viral control and immunotolerance in vivo remain(s) unknown. In this study, we defined the role of IFIH1 T946 as a partial gain-of-function variant that established the capacity for enhanced protection against specific viral challenges while concurrently promoting the risk of autoimmune disease via heightened basal and ligand-dependent signaling. We demonstrated that IFIH1 T946 promoted increased production of type I interferons in vitro and in vivo. Consistent with those findings, IFIH1 T946 enhanced anti-viral responses in vitro and viral control in vivo. In parallel, through two models of autoimmune disease, we found that the variant led to an inflammatory state that promoted autoimmunity and functioned in concert with an additional common human autoimmune risk allele.
RESULTS

Enhanced interferon signaling of PBMCs expressing IFIH1 T946
To evaluate both the role of genetic variation at IFIH1 on the risk of T1D and the relationships of the various polymorphic sites reported to be associated with autoimmunity at this locus, we re-analyzed genotyping data from the Type 1 Diabetes Genetics Consortium 23, 24 . Four rare variants (rs35744605, rs72650663, rs35667974 and rs35732034) 16 , as well as the two common non-synonymous coding variants (rs1990760 and rs3747517, which encode the amino-acid substitutions A946T and H843R, respectively), were tested separately and as haplotypes for association with T1D. Of note, the common coding variant rs3747517 has also been reported to be associated with T1D, multiple sclerosis and SLE 17, 25, 26 . Family-based single-marker analysis indicated that presence of guanine at rs3747517 ('G allele') or adenine at rs1990760 (' A allele') was associated with increased risk for T1D ( Table 1) . Haplotype analysis identified three haplotypes (H1, H2 and H4) that were significantly associated with T1D ( Table 2 ). The H1 haplotype carrying the rs3747517 'G allele' and the rs1990760 ' A allele' conferred risk for T1D, whereas the H2 and H4 haplotypes carrying the non-risk nucleotides of rs3747517 (adenine) and rs1990760 (guanine) protected against T1D ( Table 2 ). In summary, the H1 risk haplotype encoded arginine at position 843 and threonine at position 946 of IFIH1 (called 'IFIH1 R843-T946 ' (or simply 'IFIH1 R ') here). Additionally, this risk haplotype has been found to be in a moderate linkage disequilibrium and to be associated with psoriasis 16, 27, 28 .
To directly assess the effect of expression of the rs1990760 risk variant on primary human hematopoietic cells, we obtained PBMCs from healthy donors homozygous for the 'risk A allele' at rs1990760 encoding IFIH1 T946 (IFIH1 R/R ) or a 'non-risk allele' at rs1990760 (IFIH1 NR/NR ). We isolated the PBMCs and cultured them with medium alone or stimulated them with the artificial dsRNA ligand poly(I:C). PBMCs from all subjects had similar basal expression of IFIH1 mRNA ( Supplementary Fig. 1a ) that increased after treatment with poly(I:C) ( Fig. 1a and Supplementary Fig. 1b ). We found no difference between cells of the two IFIH1 genotypes in their ability to upregulate IFIH1 transcription in response to poly(I:C) ( Fig. 1a and Supplementary Fig. 1a,b ). Following stimulation with poly(I:C), PBMCs from IFIH1 R/R donors had higher expression of IFNB1 mRNA, which encodes interferon-β (IFN-β), than that of PBMCs from IFIH1 NR/NR donors ( Fig. 1b) . PBMCs from donors expressing the variant protein IFIH1 R843-T946 , which represents the product of the identified risk haplotype H1, also had higher expression of IFNB1 mRNA than that of donors expressing IFIH1 R843 alone ( Fig. 1c) . That finding was thus probably attributable to the co-occurrence of substitutions of Arg843 and Thr946. On the basis of these observations, we call the H1 haplotype (encoding IFIH1 R843-T946 ) simply 'IFIH1 R ' below (further detailed explanation of genotypes, Supplementary Table 1 ).
We next sought to determine if expression of IFIH1 R/R was associated with evidence of enhanced type I interferon signaling in vivo. Using a custom high-throughput quantitative PCR assay to measure the expression of mRNA from candidate ISGs, we found that PBMCs from healthy donors homozygous for the risk haplotype (IFIH1 R/R ) showed significantly higher basal expression of 9 of 38 candidate A r t i c l e s ISGs than that of PBMCs from healthy donors homozygous for the non-risk haplotype (IFIH1 NR/NR ); none of the ISGs were significantly downregulated in IFIH1 R/R PBMCs relative to their expression in IFIH1 NR/NR PBMCs (Fig. 1d,e and Supplementary Fig. 1c,d ). Furthermore, we quantified upregulated genes per donor to assess the presence of a type I interferon signature marked by ISGs. IFIH1 R/R donors exhibited greater number of 'interferon signature' genes that were upregulated than did IFIH1 NR/NR donors (Fig. 1f) . Hence, IFIH1 R/R led to an 'interferon signature' in healthy human subjects. Together these results showed that cells from subjects carrying the IFIH1 risk haplotype exhibited both basal and ligand-triggered enhanced IFIH1 activity and basal type I interferon signaling.
IFIH1 R promotes basal and ligand-triggered activity
In anticipation of establishing a knock-in mouse model (described below), we generated a series of cDNA expression constructs encoding mouse IFIH1 (mIFIH1) ( Fig. 2a) to assess the function of candidate variants in vitro following overexpression in HEK293T human embryonic kidney cells. Ifih1 in C57BL/6 mice encodes IFIH1 with arginine at position 843; thus, cDNA encoding IFIH1 with arginine at position 843 and threonine at position 946 (mIFIH1 R ) precisely modeled the human H1 risk haplotype encoding IFIH1 R843-T946 ( Fig. 2a) . Control constructs included mIFIH1 NR (the naturally occurring 'non-risk' (NR) Arg843 variant) and mIFIH1 P (with the amino-acid substitution I923V 16, 29 encoded by the rare rs35667974 variant that is protective (P) against T1D) ( Table 1) . While transfection of cells with each construct yielded a similar amount of mIFIH1 (Fig. 2b,c and Supplementary Fig. 2a,b) , transfection of cells with the mIFIH1 R construct led to an increase of two-to threefold in basal IFNB1 mRNA relative to that of cells transfected with the mIFIH1 NR (control) construct ( Fig. 2d) . That result was consistent with a published report showing the human IFIH1 T946 variant is a gain-of-function mutant 14 . Next we explored the ability of mIFIH1 R to respond to RNA ligands. Cells expressing each mIFIH1 construct were transfected with poly(I:C), and type I interferons were measured. Cells expressing the mIFIH1 R construct exhibited modestly but consistently higher expression of poly(I:C)-inducible IFNB1 mRNA than that of cells transfected with mIFIH1 NR (Fig. 2e,f) . In contrast, transfection of cells with the 'protective' mIFIH1 P construct ablated both basal expression of IFNB1 mRNA ( Fig. 2d ) and poly(I:C)-triggered expression of IFNB1 mRNA 16, 29 (Supplementary Fig. 2c,d) .
We next assessed IFIH1 activity in response to viral challenge. Following transfection of the various mIFIH1 constructs described above, HEK293T cells were infected with encephalomyocarditis virus (EMCV), a picornavirus specifically recognized by IFIH1 (ref. 30 ). Cells expressing mIFIH1 R had two-to threefold higher virus-triggered expression of IFNB1 mRNA than that of cells expressing mIFIH1 NR , at 9 h after infection ( Fig. 2g) ; in contrast, cells expressing mIFIH1 P exhibited no such response to viral challenge ( Fig. 2g) . In a second test, cells expressing mIFIH1 R had higher expression of type I interferons than that of cells expressing mIFIH1 NR , concomitant with lower viral load, following infection with West Nile virus ( Supplementary  Fig. 2d-g) , which also triggers the induction of type I interferons, in part through IFIH1 (ref. 6 ). These combined results demonstrated that mIFIH1 R promoted heightened basal and ligand-triggered signaling and enhanced responsiveness to RNA viruses that express IFIH1 ligands during their replication cycle.
Enhanced type I interferons and viral protection of mice
To gain better understanding of the function of IFIH1 R in both autoimmune disease and viral control, we generated a mouse strain with an Ifih1 allele that precisely mimicked the human IFIH1 R (IFIH1 R843-T946 ) haplotype. We used homologous recombination to generate founder mice on the non-autoimmune-prone C57BL/6 genetic background ( Supplementary Fig. 3a,b) . Gene targeting achieved the variantspecific coding change (encoding the substitution A946T) in exon 15 of Ifih1 without affecting Ifih1 mRNA ( Supplementary Fig. 3c ). When we intercrossed heterozygous Ifih1 NR/R mice, we observed partial embryonic death, with substantially fewer homozygous Ifih1 R/R offspring than expected ( Fig. 3a) . While newborn mice heterozygous (Ifih1 NR/R ) or homozygous (Ifih1 R/R ) for the risk allele (the mouse equivalent of the H1 haplotype allele) seemed to be healthy and exhibited normal weight gain and a normal frequency of lymphoid and myeloid subsets (data not shown), they exhibited a trend for a greater number of splenocytes than that of their Ifih1 NR/NR (control) littermates at 2-12 months of age ( Supplementary Fig. 3d ). Similar to our findings for human PBMCs ex vivo, splenocytes from Ifih1 R/R mice had higher basal expression of Ifnb1 mRNA and mRNA from multiple ISGs, including Mx1, Ifit1 and Isg15, than that of splenocytes from Ifih1 NR/NR mice (Fig. 3b,c) .
To investigate whether the H1 haplotype conferred an in vivo advantage against viral pathogens, we assessed the ability of Ifih1 R/R mice to control an EMCV challenge. After intraperitoneal injection of EMCV, ~75% of the Ifih1 NR/NR mice succumbed to EMCV infection within 8 d ( Fig. 4) . However, both Ifih1 NR/R mice and Ifih1 R/R mice were significantly more protected against EMCV than were their Ifih1 NR/NR littermates. Together our findings showed that 'IFIH1 R mice' , whether Ifih1 NR/R or Ifih1 R/R , manifested elevated basal IFIH1 activity, which led to an 'ISG signature' and a modest auto-inflammatory state. In parallel, they had enhanced resistance to challenge with an IFIH1-specific, RNA viral pathogen.
IFIH1 R promotes disease in mouse autoimmune models
We were interested in determining whether IFIH1 R has a causal role in the promotion of autoimmune disease. Streptozocin (STZ), a DNA-alkylating agent that is selectively toxic to pancreatic β-cells, can induce T1D in C57BL/6 mice. We used an STZ dosing regimen that did not affect the concentration of glucose in the blood of the Ifih1 NR/NR (2), with the amino acid encoded below, and the frequency of the haplotype (Freq).
(control) littermates of Ifih1 R/R and Ifih1 NR/R mice (Fig. 5a,b) . However, Ifih1 R/R mice treated with that same regimen had a greater incidence of diabetes than that of Ifih1 NR/NR mice, while Ifih1 NR/R mice showed an intermediate incidence ( Fig. 5a,b) . As human variants do not occur in isolation, we next intercrossed the IFIH1 R mice with mice of another risk model consisting of a single-nucleotide change in the gene encoding the phosphatase PTPN22 (Ptpn22) 31 . This strain (called 'PTPN22 R ' here) mimics the extensively studied human autoimmune risk variant rs2476601 that leads to an aminoacid substitution in a key interacting domain of the phosphatase. PTPN22 R mice on a mixed 129/BL6 background exhibit more STZinduced diabetes than that of their littermates expressing the 'nonrisk' (NR) Ptpn22 gene (PTPN22 NR ) 31 . For these experiments we used PTPN22 R mice that had been fully backcrossed onto the C57BL/6 background and challenged mice of single or combined genotype with STZ to assess potential synergy in the development of T1D. Ifih1 NR/NR Ptpn22 NR/R mice exhibited a low rate of diabetes development, while Ifih1 NR/R Ptpn22 NR/NR mice and Ifih1 NR/NR Ptpn22 NR/NR (control) mice failed to develop disease ( Fig. 5c,d) . In contrast, Ifih1 NR/R Ptpn22 NR/R mice displayed a greater incidence and rate of diabetes than that of mice of the other genotypes assessed ( Fig. 5c,d) .
The Ifih1 NR/R Ptpn22 NR/R (compound heterozygous) mice displayed early-stage and late-stage focal or focally extensive pancreatitis and pancreatic atrophy ( Supplementary Fig. 4b ) not seen in the diabetic Ifih1 NR/NR Ptpn22 NR/R (heterozygous) mice ( Supplementary Fig. 4a ). Ifih1 NR/R Ptpn22 NR/R mice also exhibited atrophic and sclerotic pancreatic tissue that contained remnants of pancreatic ducts with damaged islets embedded within fibrous tissues or scattered among clusters of fibroblasts and inflammatory cells (Supplementary Fig. 4b ).
Together these data demonstrated an additive effect in vivo of two human risk alleles in promoting autoimmune disease. As IFIH1 R is also associated with risk for SLE in humans, we next investigated whether the mouse allele directly promoted lupus; for this we used the BM12 model of lupus. The BM12 strain (derived from the C57BL/6 strain) has a three-amino-acid change in the major histocompatibility complex class II molecule H2-Ab1 b (ref. 32 ). Adoptive A r t i c l e s transfer of BM12 CD4 + T cells into C57BL/6 recipients initiates autoimmune germinal-center responses that generate autoantibodies directed against dsDNA and the Smith ribonucleoprotein (smRNP) within ~3 weeks of cell transfer 33, 34 . We transferred CD4 + T cells from BM12 mice into Ifih1 R/R or Ifih1 NR/R mice or their Ifih1 NR/NR (control) littermates. All strains displayed similar titers of autoantibodies at 3 weeks after cell transfer (Fig. 5e,f and Supplementary Fig. 4c) . In contrast, IgG and IgG2c autoantibodies directed against dsDNA and smRNP remained elevated in Ifih1 R/R mice at 12 weeks after cell transfer, whereas those titers returned to baseline in Ifih1 NR/NR mice (Fig. 5e,f and Supplementary Fig. 4c) . Similar trends were observed for Ifih1 NR/R mice (Fig. 5e,f and Supplementary Fig. 4c ). Additionally, we observed a trend toward greater spleen size in Ifih1 R/R mice than in Ifih1 NR/NR mice (Supplementary Fig. 4d ). The sustained, BM12cell-triggered autoantibody response observed in Ifih1 R/R mice might mimic the autoantibody responses of patients with SLE who have a 'type I interferon signature' and is consistent with clinical features of patients with SLE in whom anti-dsDNA titers have been shown to correlate with the IFIH1 rs1990760 risk allele 35 . Together our findings demonstrated that IFIH1 R was able to facilitate autoimmune disease in response to a triggering event and was able to function coordinately with additional risk variants in altering tolerance.
Enhanced activity of IFIH1 R toward self RNA ligands
Published work has demonstrated that in addition to identifying ligands of viral dsRNA and single-stranded RNA, IFIH1 might be triggered by dsRNA structures within endogenous RNA [36] [37] [38] [39] . We hypothesized that the observed embryonic survival defect ( Fig. 3a) and increased production of basal type I interferons (Fig. 3c,d to enhanced responsiveness of IFIH1 R to self RNA ligands. We tested our hypothesis in a cell line engineered to limit the processing of self RNA: HEK293T cells lacking the dsRNA-specific adenosine deaminase ADAR1 (ADAR-null cells). ADAR1 performs adenosine-to-inosine RNA editing that is proposed to destabilize duplexes formed from inverted repetitive elements within self RNAs and thereby prevents IFIH1 from sensing those cytoplasmic RNAs 36, 37 . Consistent with that role, bi-allelic missense mutations in human ADAR, like dominant IFIH1 mutations, result in a severe congenital interferonopathy 40 , and disruption of ADAR in HEK293T cells leads to a substantial increase in signaling after overexpression of IFIH1 (ref. 37) . We therefore assessed the effect of the candidate mIFIH1 constructs described above ( Fig. 2a) in control (ADAR-sufficient) and ADAR-null 293T cells. As noted above (Fig. 2) , the mIFIH1 NR and mIFIH1 R constructs yielded similar amounts of mIFIH1 protein, as 'read out' by both the geometric mean fluorescent intensity of green fluorescent protein (GFP) and frequency of cells expressing a cis-linked gene encoding a GFP reporter (Fig. 6a,b) . Recapitulating our results reported above, ADAR-sufficient (control) HEK293T cells expressing mIFIH1 R had higher basal expression of IFNB1 mRNA than that of ADAR-sufficient HEK293T cells expressing mIFIH1 NR (control 293T cells) (Fig. 6c) . However, expression of IFNB1 mRNA was significantly (~50-fold) higher in ADAR-null cells expressing mIFIH1 NR than in control 293T cells, and that enhancement was further amplified in ADAR-null cells expressing mIFIH1 R (~100-fold higher than that of control 293T cells) ( Fig. 6d,e) , consistent with the recognition of accumulated self dsRNA ligands. Together these results indicated that IFIH1 R was hypersensitive to the RNA self ligands present in the ADAR-null cells and thereby generated a stronger type I interferon signal.
DISCUSSION
While IFIH1 R has been linked to multiple autoimmune disorders, the functional effect of this isoform on immune systems has remained largely unexplored. Notably, despite strong evidence of risk for autoimmunity, the frequency of this risk haplotype is relatively high in A r t i c l e s some human populations, which suggests that it might also provide a selective advantage in the setting of infectious challenge. In this study, we comprehensively assessed the function of IFIH1 R both in vitro and in vivo in mouse and human PBMCs. Our findings demonstrated that IFIH1 R facilitated enhanced ligand-dependent viral sensing while also increasing the risk for autoimmunity. First, we found that PBMCs from healthy donors expressing IFIH1 R exhibited increased ligandtriggered production of type I interferons. Strikingly, PBMCs from people homozygous for risk alleles also showed significantly higher baseline expression of ISGs than that of PBMCs expressing IFIH1 A946 , consistent with a 'basal type I interferon signature' . Published work has identified an type I interferon signature in both asymptomatic subjects and affected subjects from a family with a rare gain-of-function mutation in sequence encoding the IFIH1 helicase domain 12, 41 .
Here we expanded on those observations and showed a type I interferon signature in the majority of healthy subjects defined on the basis of expression of IFIH1 R . Notably, published work has indicated that rs3747517 leads to an amino-acid change (Arg843) within the helicase domain of IFIH1 with altered protein function 28 . Our data showed a dominant role for IFIH1 T946 in the enhanced activity driven by the IFIH1 R843-T946 risk haplotype. While the possibility of an effect of the allele encoding Arg843 on some aspects of the function of IFIH1 cannot be ruled out, we note that the allele encoding Arg843 is associated with risk for T1D when it occurs on the same haplotype as the allele encoding Thr946, in support of our conclusion that IFIH1 T946 was driving the phenotype. Second, using carefully matched expression of risk and non-risk proteins, we showed that IFIH1 R exhibited heightened basal and ligand-triggered activity that was independent of potential variant-mediated alterations in the expression of IFIH1 protein, as suggested by published studies accounting for the effect of this amino-acid change 42, 43 . Moreover, consistent with the proposal of a protective effect in an in vivo viral challenge, we showed that cells expressing mIFIH1 R displayed greater activity than that of cells expressing mIFIH1 NR in response to two relevant RNA viruses. Third, in a mouse model, we showed that IFIH1 R led to a gene-dosedependent increase in splenic expression of mRNA encoding type I interferons and mRNA from ISGs. Most notably, the risk variant also mediated in vivo protection against a lethal viral challenge, indicative of a mechanism whereby selection could act on the variant and increase its frequency in the population. Fourth, we found that, consistent with its association with human autoimmunity, IFIH1 R promoted disease in mouse models of both diabetes and lupus. Notably, our study also provided an example wherein two human autoimmune genome-wide-association-study risk variants were modeled in unison and displayed an additive effect in promoting disease. Finally, we showed that homozygous expression of IFIH1 T946 led to more fetal loss than did expression of IFIH1 A946 and that this phenotype was probably due to an enhanced ability to recognize RNA self ligands.
In contrast to earlier work, our combined data demonstrated that the IFIH1 T946 variant exhibited enhanced ligand-dependent signaling in vivo and in vitro relative to that of the IFIH1 A946 variant. Consistent with our findings, a published report has shown that overexpression of human IFIH1 T946 promotes greater basal levels of type I interferons than does overexpression of IFIH1 A946 (ref. 14) . However, in contrast, that study reported that the IFIH1 T946 variant is unable to recognize RNA ligands or trigger signaling, due to a lack of ATPase activity 14 . Our data showed that IFIH1 T946 recognized both synthetic dsRNA ligands and viral RNA ligands, which led to an increase mRNA encoding in type I interferons (relative to that induced by IFIH1 A946 ), as assessed in three different systems in vitro and/or in vivo. The differences between our work here and that earlier study 14 might reflect different time courses and/or reagents. Of note, the requirement for the ligand-triggering of IFIH1 activity might reflect the location of missense mutation within IFIH1 with constitutive activation from mutations that alter the helicase domain 44 versus a mutation that alters the C-terminal domain (IFIH1 T946 ) that functions to modulate responsiveness to RNA ligands. Additional structural modeling will be needed to address these possibilities.
Notably, in addition to indicating an enhanced response to viral RNAs, our data also indicated an enhanced response to RNA self ligands in the context of the biological effect of IFIH1 R . Through the use of ADAR-null cells, which generate more endogenous self RNAs, we provided evidence that IFIH1 R recognized and displayed heightened activity toward self RNA 37 . Correspondingly, we observed higher basal ISG expression in both the Ifih1 R/R mice and in healthy subjects with IFIH1 R , relative to the expression of those ISGs in mice or subjects lacking the risk allele. While the relative increase in the production of type I interferons associated with the risk allele was modest, a low increase in interferons correlated with a disease phenotype. Similarly, type I interferons are frequently too low to be measured consistently, which has led to the use of an 'interferon signature' as biomarker for Aicardi-Goutières syndrome 45 . Whether IFIH1 R recognizes different ligands or a greater breadth of ligands relative to the ligands recognized by IFIH1 NR remains to be determined. Overall, our data support the hypothesis that IFIH1 R leads to an enhanced 'interferon state' through the recognition of self RNAs and that this might increase the risk for autoimmune disease with or without concomitant viral challenge. 
A r t i c l e s
Our viral-challenge data support the possibility that the IFIH1 R843-T946 haplotype might have been subject to positive selection in humans, given its ability to promote an improved response to viral infection. Published population-genetics studies have noted a high degree of nucleotide diversity and strong population differences at IFIH1. Action of positive selection on IFIH1 has been proposed for the SNP rs10930046 (which encodes the substitution R460H) 46 . A study of intracellular pattern-recognition RIG-I-like receptors has reported a second signature of positive selection at rs3747517 (which encodes the substitution R843H) in African and Asian populations 47 . Furthermore, haplotypes of IFIH1 encoding histidine at position 843 and threonine at position 946 (IFIH1 H843-T946 ) have been reported to correlate with the resolution of infection with hepatitis C virus 28 . Notably, we found that IFIH1 H843-T946 was very rare in our data, consistent with other reports 48, 49 . Thus, at the populat ion level, the effect of the common risk haplotype (IFIH1 R843-T946 ) on the response to viral challenge and risk of autoimmune disease is probably important, whereas the effect of the rare IFIH1 H843-T946 haplotype would be negligible. Overall, our functional and population data suggest that non-synonymous substitutions at IFIH1 might act as a double-edged sword, protecting from illness and promoting illness at the same time, and that this might affect their frequency in the population.
Notably, we identified a partial embryonic survival defect in the homozygous Ifih1 R/R mice, which raised the possibility of a similar effect on human fertility. However, the frequency of the IFIH1 R allele would suggest that this is unlikely. Furthermore, increased fetal loss has not been reported for more-severe gain-of-function variants that lead to early-onset interferonopathies. In contrast, embryonic death has been described in several mouse strains with alterations in the IFIH1 signaling cascade 37, 50 . Thus, we anticipate that the threshold for type I interferons to mediate embryonic death differs in mice versus humans.
In summary, we have identified the function for the IFIH1 T946 risk variant in regulating a key antiviral sensing pathway in which it both defended against viral infection and bolstered responses to self RNA. Our data have provided a demonstration of the power of a combinatorial approach that made use of studies of healthy human subjects in association with mouse modeling to assess the effect of candidate genome-wide-association-study variants and to functionally model combinatorial effect of additional variants; this is an important consideration, as disease-associated genetic variants probably do not function in isolation. Our combined work has provided new insight into functional mechanism(s) in the setting of endogenous gene expression and candidate disease initiators. Application of this approach to other risk or protective variants might promote a more rapid advance in the understanding of human disease mechanism.
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